Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4462-4469

  Gisselbrecht, Christian ^a   Schmitz, Norbert ^e   Mounier, Nicolas ^b   Gill, Devinder Singh ^h   Linch, David C ^k   Trneny, Marek ^m   Bosly, Andre ⁿ   Milpied, Noel J ^c   Radford, John ^l   Ketterer, Nicolas ^o   Shpilberg, Ofer ^p   Duḧrsen, Ulrich ^f   Hagberg, Hans ^q   Ma, David D ⁱ   Viardot, Andreas ^g   Lowenthal, Ray ^j   Brier̀e, Josette ^a   Salles, Gilles ^d   Moskowitz, Craig H ^r   Glass, Bertram ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d UNIVERSITÉ DE LYON   (France)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h PRINCESS ALEXANDRA HOSPITAL   (Australia)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j ROYAL HOBART HOSPITAL   (Australia)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^o Clinique Bois Cerf   (Switzerland)

^p RABIN MEDICAL CENTER   (Israel)

^q UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CD20 ANTIGEN; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; RITUXIMAB;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84871731101     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.9416     Document Type: Article

References (31)

1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
2. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
3. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
4. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005
5. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
6. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007
7. Ziepert M, Hasenclever D, Kuhnt E, et al: Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28:2373-2380, 2010
8. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
9. Coiffier B, Thieblemont C, Van Den Neste E, et al: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045, 2010
10. Bosly A, Coiffier B, Gisselbrecht C, et al: Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 10:1615-1623, 1992
11. Vellenga E, van Putten WL, van't Veer MB, et al: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial. Blood 111:537-543, 2008
12. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006
13. Khouri IF, Saliba RM, Hosing C, et al: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23:2240-2247, 2005
14. Horwitz SM, Negrin RS, Blume KG, et al: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777-783, 2004
15. Haioun C, Mounier N, Emile JF, et al: Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol 20:1985-1992, 2009
16. Kewalramani T, Zelenetz AD, Nimer SD, et al: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004
17. Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988
18. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010
19. Blay J, Gomez F, Sebban C, et al: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial - Parma Group. Blood 92:3562-3568, 1998
20. Hamlin PA, Zelenetz AD, Kewalramani T, et al: Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989-1996, 2003
21. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI-Sponsored International Working Group. J Clin Oncol 17:1244, 1999
22. Thieblemont C, Briere J, Mounier N, et al: The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A Bio-CORAL study. J Clin Oncol 29:4079-4087, 2011
23. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (Rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene 24:2121-2143, 2005
24. Müller C, Murawski N, Wiesen MH, et al: The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119:3276-3284, 2012
25. Riihijärvi S, Taskinen M, Jerkeman M, et al: Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 86:124-128, 2011
26. Ng CM, Bruno R, Combs D, et al: Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45:792-801, 2005
27. Janssen I, Powell LH, Kazlauskaite R, et al: Testosterone and visceral fat in midlife women: The Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity 18:604-610, 2010
28. Martín A, Conde E, Arnan M, et al: R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome - A GEL/TAMO study. Haematologica 93:1829-1836, 2008
29. van Kampen RJ, Canals C, Schouten HC, et al: Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29:1342-1348, 2011
30. Thomson KJ, Morris EC, Bloor A, et al: Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27:426-432, 2009
31. Glass C, Hasenkamp J, Goerlitz A, et al: Allogeneic stem cell transplantation with intermediate conditioning is effective in high risk relapse and progressive disease of aggressive non-Hodgkin lymphoma. Blood 114:3379, 2009 (abstr)